Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 350-357

  Dayton, Alex ^a   Selvendiran, Karuppaiyah ^a   Meduru, Sarath ^a   Khan, Mahmood ^a   Kuppusamy, M Lakshmi ^a   Naidu, Shan ^a   Kálai, Tamás ^b   Hideg, Kálmán ^b   Kuppusamy, Periannan ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 BIS(4 FLUOROBENZYLIDENE) 1 [(2,2,5,5 TETRAMETHYL 2,5 DIHYDRO 1 HYDROXY PYRROL 3 YL)METHYL]PIPERIDIN 4 ONE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CASPASE 3; DOXORUBICIN; FATTY ACID SYNTHASE; HO 3867; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SYNTHESIS; ENZYME INHIBITION; HEART FUNCTION; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; AORTA; BREAST NEOPLASMS; CARDIOTONIC AGENTS; CASPASES; CELL LINE, TUMOR; CYCLINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART DISEASES; HUMANS; MALE; MICE; MICE, INBRED BALB C; PIPERIDONES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 80054790399     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.183681     Document Type: Article

References (42)

1. Cao Z and Li Y (2004) Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 489:39-48. (Pubitemid 38520069)
2. Coticchia CM, Revankar CM, Deb TB, Dickson RB, and Johnson MD (2009) Calmodulin modulates Akt activity in human breast cancer cell lines. Breast Cancer Res Treat 115:545-560.
3. Danz ED, Skramsted J, Henry N, Bennett JA, and Keller RS (2009) Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46:1589-1597.
4. Dunn J (1994) Doxorubicin-induced cardiomyopathy. J Pediatr Oncol Nurs 11:152-160.
5. Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, and Rochefort H (2007) Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer 120:224-229. (Pubitemid 44970426)
6. Ewer MS and Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7:564-575.
7. Ilangovan G, Li H, Zweier JL, Krishna MC, Mitchell JB, and Kuppusamy P (2002) In vivo measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: effect of carbogen-breathing. Magn Reson Med 48:723-730.
8. Jain D (2000) Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 7:53-62.
9. Jin W, Wu L, Liang K, Liu B, Lu Y, and Fan Z (2003) Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89:185-191. (Pubitemid 36897956)
10. Kaìlai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P, and Hideg K (2011) Synthesis of N-substituted 3,5-bis(arylidene)-4- piperidones with high antitumor and antioxidant activity. J Med Chem 54:5414-5421.
11. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, and Kotamraju S (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235:119-124. (Pubitemid 34777848)
12. Khan M, Varadharaj S, Shobha JC, Naidu MU, Parinandi NL, Kutala VK, and Kuppusamy P (2006) C-phycocyanin ameliorates doxorubicin-induced oxidative stress and apoptosis in adult rat cardiomyocytes. J Cardiovasc Pharmacol 47:9-20. (Pubitemid 44378219)
13. Kim J and Freeman MR (2003) JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 79:321-328. (Pubitemid 36750939)
14. 2+increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med 38:535-545.
15. Kuppusamy P, Afeworki M, Shankar RA, Coffin D, Krishna MC, Hahn SM, Mitchell JB, and Zweier JL (1998) In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. Cancer Res 58:1562-1568. (Pubitemid 28193625)
16. Kuppusamy P, Li H, Ilangovan G, Cardounel AJ, Zweier JL, Yamada K, Krishna MC, and Mitchell JB (2002) Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 62:307-312. (Pubitemid 34074020)
17. Li J, Liu H, Ramachandran S, Waypa GB, Yin JJ, Li CQ, Han M, Huang HH, Sillard WW, Vanden Hoek TL, et al. (2010) Grape seed proanthocyanidins ameliorate Doxorubicin-induced cardiotoxicity. Am J Chin Med 38:569-584.
18. Liu H, Liu Y, and Zhang JT (2008) A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther 7:263-270. (Pubitemid 351302520)
19. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229. (Pubitemid 38720829)
20. Mitchell JB, Krishna MC, Kuppusamy P, Cook JA, and Russo A (2001) Protection against oxidative stress by nitroxides. Exp Biol Med (Maywood) 226:620-621. (Pubitemid 32619596)
21. Pivot X, Asmar L, Buzdar AU, Valero V, and Hortobagyi G (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82:529-534. (Pubitemid 30085185)
22. Rossi A, Colantuoni G, Maione P, Ferrara C, Airoma G, Barzelloni ML, Castaldo V, and Gridelli C (2005) Chemotherapy of breast cancer in the elderly. Curr Med Chem 12:297-310. (Pubitemid 40305621)
23. Samuni Y, Gamson J, Samuni A, Yamada K, Russo A, Krishna MC, and Mitchell JB (2004) Factors influencing nitroxide reduction and cytotoxicity in vitro. Antioxid Redox Signal 6:587-595. (Pubitemid 38625378)
24. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kálai T, Hideg K, et al. (2010a) Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells. Free Radic Biol Med 48:1228-1235.
25. Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, Rivera BK, Kálai T, Hideg K, and Kuppusamy P (2010b) HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 8:1188-1197.
26. Selvendiran K, Kuppusamy ML, Bratasz A, Tong L, Rivera BK, Rink C, Sen CK, Kálai T, Hideg K, and Kuppusamy P (2009) Inhibition of vascular smooth-muscle cell proliferation and arterial restenosis by HO-3867, a novel synthetic curcuminoid, through up-regulation of PTEN expression. J Pharmacol Exp Ther 329:959-966.
27. Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kálai T, Hideg K, et al. (2010c) Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 9:1169-1179.
28. Sinha BK and Mimnaugh EG (1990) Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med 8:567-581. (Pubitemid 20204420)
29. Small GW, Shi YY, Higgins LS, and Orlowski RZ (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67:4459-4466. (Pubitemid 46815096)
30. Srinivasan S, Koduru S, Kumar R, Venguswamy G, Kyprianou N, and Damodaran C (2009) Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. Int J Cancer 125:961-967.
31. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234. (Pubitemid 43336035)
32. Takemura G and Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352. (Pubitemid 46295436)
33. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, and Zuppinger C (2006) Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41:845-854. (Pubitemid 44635571)
34. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, and Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389-405. (Pubitemid 44362995)
35. Unverferth DV, Magorien RD, Leier CV, and Balcerzak SP (1982) Doxorubicin cardiotoxicity. Cancer Treat Rev 9:149-164. (Pubitemid 13239947)
36. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, and Menendez JA (2008) Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 41:59-85. (Pubitemid 351147647)
37. Vibet S, Goupille C, Bougnoux P, Steghens JP, Goré J, and Mahéo K (2008) Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 44:1483-1491.
38. Wrede CE, Dickson LM, Lingohr MK, Briaud I, and Rhodes CJ (2002) Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J Biol Chem 277:49676-49684. (Pubitemid 36014411)
39. Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, and Vadgama JV (2008) Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 10:R3.
40. Yamada KI, Kuppusamy P, English S, Yoo J, Irie A, Subramanian S, Mitchell JB, and Krishna MC (2002) Feasibility and assessment of non-invasive in vivo redox status using electron paramagnetic resonance imaging. Acta Radiol 43:433-440.
41. Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HC, Castilho RF, Coletta RD, Vercesi AE, and Graner E (2011) Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Invest 91:232-240.
42. Zhou S, Palmeira CM, and Wallace KB (2001) Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 121:151-157. (Pubitemid 32441771)